Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3512421 | 1.00 | AKR1B1 (0.33) | AKR1B1 | |
| SCHEMBL6136757 | 1.00 | AKR1B1 (0.33) | AKR1B1 | |
| SCHEMBL8891164 | 1.00 | AKR1B1 (0.33) | AKR1B1 | |
| SCHEMBL22718863 | 1.00 | AKR1B1 (0.33) | AKR1B1 | |
| SCHEMBL2319494 | 0.87 | AKR1B1 (0.31) | AKR1B1 | |
| SCHEMBL2319604 | 0.87 | AKR1B1 (0.31) | AKR1B1 | |
| SCHEMBL3357559 | 0.87 | AKR1B1 (0.31) | AKR1B1 | |
| SCHEMBL2323878 | 0.87 | AKR1B1 (0.31) | AKR1B1 | |
| SCHEMBL183808 | 0.76 | AKR1B1 (0.36) | AKR1B1 | |
| SCHEMBL4288128 | 0.74 | AKR1B1 (0.36) | AKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12545944-B2 | Method of detection | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2026-02-10 | — | — | US | disclosed |
| EP-4654962-A1 | ANTI-BACTERIAL EFFECT OF HALOGENATED FLUORESCEINS AGAINST COLISTIN-RESISTANT GRAM-NEGATIVE BACTERIA | Provectus Pharmatech, Inc. (US) | 2025-12-03 | — | — | EP | disclosed |
| US-20240325341-A1 | ANTI-BACTERIAL EFFECT OF HALOGENATED FLUORESCEINS AGAINST COLISTIN-RESISTANT GRAM-NEGATIVE BACTERIA | PROVECTUS PHARMATECH, INC. (US) | 2024-10-03 | — | — | US | disclosed |
| WO-2024206220-A1 | ANTI-BACTERIAL EFFECT OF HALOGENATED FLUORESCEINS AGAINST COLISTIN-RESISTANT GRAM-NEGATIVE BACTERIA | PROVECTUS PHARMATECH, INC. (US) | 2024-10-03 | — | — | WO | disclosed |
| US-20210330718-A1 | COMPOSITION AND METHODS FOR TREATING CANCER AND IMMUNE DISORDERS USING VEILLONELLA BACTERIA | HORIZON TECHNOLOGY FINANCE CORPORATION | 2021-10-28 | — | — | US | disclosed |
| US-11090341-B2 | Compositions and methods for treating cancer and immune disorders using Veillonella bacteria | EVELO BIOSCIENCES, INC. (US) | 2021-08-17 | — | — | US | disclosed |
| EP-3589742-B1 | METHOD OF DETECTION | IMPERIAL COLLEGE INNOVATIONS LTD (GB) | 2021-08-04 | — | — | EP | disclosed |
| US-20210113628-A1 | INTRACELLULAR DELIVERY OF BIOMOLECULES TO MODIFY IMMUNE RESPONSE | SQZ BIOTECHNOLOGIES CO (US) | 2021-04-22 | — | — | US | disclosed |
| EP-3749340-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER AND IMMUNE DISORDERS USING VEILLONELLA BACTERIA | Evelo Biosciences, Inc. (US) | 2020-12-16 | — | — | EP | disclosed |
| CN-112074283-A | Compositions and methods for treating cancer and immune disorders using bacteria of the genus veillonella | 伊夫罗生物科学公司 | 2020-12-11 | — | — | CN | disclosed |
| US-20080234185-A1 | Use of Dmbt1 for Capturing Sulphate and Phosphate Group Exposing Agents | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2008-09-25 | — | — | US | disclosed |
| WO-2005079834-A9 | USE OF DMBT1 FOR CAPTURING SULPHATE AND PHOSPHATE GROUP EXPOSING AGENTS | DKFZ KREBSFORSCHUNGSZENTRUM (DE) | 2005-10-27 | — | — | WO | disclosed |
| EP-1568374-A1 | Use of DMBT1 for capturing sulphate and phosphate group exposing agents | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) | 2005-08-31 | — | — | EP | disclosed |
| WO-2002078634-A2 | METHODS FOR USING KDOP AND KDOP SYNTHASE INHIBITORS FOR THE TREATMENT OF BACTERIAL INFECTION | FAZIX CORPORATION (US) | 2002-10-10 | — | — | WO | disclosed |
| US-5952313-A | COMPOSITION FOR ANTAGONIZING GRAM NEGATIVE BACTERIAL ENDOTOXIC ACTIVITY, COMPRISING A PHARMACEUTICALLY ACCEPTABLE CARRIER AND AN ANTAGONIZING AMOUNT OF A LIPOPOLYSACCHARIDE FROM A RHIZOBIUM ETLI; TREATMENT OF SEPTIC SHOCK OR TOXIC SHOCK | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 1999-09-14 | — | — | US | disclosed |
| US-5830860-A | Peptides with bactericidal activity and endotoxin neutralizing activity for gram negative bacteria and methods for their use | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 1998-11-03 | — | — | US | disclosed |
| US-5786324-A | Synthetic peptides with bactericidal activity and endotoxin neutralizing activity for gram negative bacteria and methods for their use | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 1998-07-28 | — | — | US | disclosed |
| US-5648343-A | ADMINISTERING A LIPID | THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION (US) | 1997-07-15 | — | — | US | disclosed |
| EP-0748327-A1 | STRUCTURE OF A NOVEL LIPID A AND METHODS UTILIZING SAME | THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 1996-12-18 | — | — | EP | disclosed |
| WO-1995023156-A1 | STRUCTURE OF A NOVEL LIPID A AND METHODS UTILIZING SAME | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 1995-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12545944-B2 | Method of detection | PHOSPHO1, NAAA, LIPA | AKR1B1 3878/4885 |
| US-20240325341-A1 | ANTI-BACTERIAL EFFECT OF HALOGENATED FLUORESCEINS AGAINST COLISTIN-RESISTANT GRAM-NEGATIVE BACTERIA | LBR, IK, BCR | AKR1B1 4052/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.